Palvella Therapeutics (PVLA) Total Current Liabilities (2013 - 2026)

Palvella Therapeutics (PVLA) has 14 years of Total Current Liabilities data on file, last reported at $9.1 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $9.1 million, up 1.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.1 million (up 1.47% YoY), and the FY2025 annual result was $11.3 million, down 5.77% from the prior year.
• Total Current Liabilities fell to $9.1 million in Q1 2026 per PVLA's latest filing, from $11.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $42.9 million in Q1 2023 and troughed at $2.4 million in Q4 2023.
• A 5-year average of $19.6 million and a median of $11.3 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities plunged 93.55% in 2023, then soared 410.08% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $36.6 million in 2022, then sank by 93.55% to $2.4 million in 2023, then soared by 410.08% to $12.0 million in 2024, then slipped by 5.77% to $11.3 million in 2025, then dropped by 19.65% to $9.1 million in 2026.
• Business Quant data shows PVLA's Total Current Liabilities at $9.1 million in Q1 2026, $11.3 million in Q4 2025, and $10.3 million in Q3 2025.